Relationships between Alexithymia, Emotional Control, and Quality of Life in Patients with Inflammatory Bowel DiseaseVerissimo R.a · Mota-Cardoso R.a · Taylor G.b
a Psicologia Médica, Faculdade de Medicina do Porto/H.S. João, Al Hernani Monteiro, Porto, Portugal; b Department of Psychiatry, University of Toronto and Mount Sinai Hospital, Toronto, Ont., Canada
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Background: Although the constructs of alexithymia and emotional control have been associated with physical health, the relationship between these constructs is unclear and their influence on health-related quality of life has not been investigated previously. This study examined the relationships between alexithymia, emotional control, and quality of life in 74 patients with inflammatory bowel disease (IBD). Methods: The subjects completed the 20-item Toronto Alexithymia Scale (TAS-20), the Emotional Expression and Control Scale (EEC), and the Inflammatory Bowel Disease Questionnaire (IBDQ) for assessing quality of life. Results: The TAS-20 correlated negatively and significantly with the IBDQ global score and with subscales assessing bowel symptoms, systemic symptoms, and emotional functioning; the emotional control subscale of the EEC correlated positively and significantly with these measures. Although the TAS-20 correlated significantly and negatively with the emotional control subscale, alexithymia and quality of life scores were unrelated to subscales of the EEC assessing tendencies to either hold back or express emotions. A hierarchical stepwise multiple regression analysis revealed that alexithymia and, to a lesser extent, emotional control play a role in predicting quality of life in patients with IBD. Conclusions: Alexithymia and emotional control are negatively related constructs and each construct has an independent influence on the subjective health status of patients with IBD.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.